The US Food and Drug Administration (FDA) has ordered label changes for bluebird bio's Skysona (elivaldogene autotemcel) due to blood cancer risks associated with the gene therapy product.

Shares of Florida-USA-based drug developer Veru fell more than 4% to $3.58 in early trading, after it announced selection of ...